CGRP Antagonists Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global CGRP Antagonists market size was valued at USD 2935.6 million in 2022 and is forecast to a readjusted size of USD 10000 million by 2029 with a CAGR of 19.1% during review period.

CGRP (calcitonin gene-related peptide) is a protein released around the nervous system of the brain. CGRP is widely distributed in peripheral neurons and central neurons, and its role is to participate in the process of pain transmission in the nervous system.

The CGRP (calprotectin gene-related peptide) antagonist market is a rapidly growing field focused on developing drugs to treat migraine and other neuropathic pain symptoms. These drugs reduce or prevent migraine attacks by inhibiting the effects of CGRP, providing patients with more effective pain management options. Several CGRP antagonists are already approved and in use on the market, and more new drugs are in development. Growth in this market is driven by expanding patient demand and scientific research, providing hope and an opportunity to improve the quality of life for migraine sufferers.

Report includes an overview of the development of the CGRP Antagonists industry chain, the market status of Hospital (Monoclonal Antibodies, CGRP Receptor Inhibitor), Clinic (Monoclonal Antibodies, CGRP Receptor Inhibitor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of CGRP Antagonists.

Regionally, the report analyzes the CGRP Antagonists markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global CGRP Antagonists market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the CGRP Antagonists market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the CGRP Antagonists industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Monoclonal Antibodies, CGRP Receptor Inhibitor).

Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the CGRP Antagonists market.

Regional Analysis: The report involves examining the CGRP Antagonists market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the CGRP Antagonists market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to CGRP Antagonists:

Company Analysis: Report covers individual CGRP Antagonists manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards CGRP Antagonists This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to CGRP Antagonists. It assesses the current state, advancements, and potential future developments in CGRP Antagonists areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the CGRP Antagonists market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

   PFIZER INC(Biohaven)
   ABBVIE INC
   Amgen
   Teva
   Eli Lilly and Company
   Lundbeck
   Novartis

   Monoclonal Antibodies
   CGRP Receptor Inhibitor

   Hospital
   Clinic
   Other

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the CGRP antagonists market in 2025?

The CGRP antagonists market is bolstered by strong clinical efficacy in treating migraine and chronic pain, with several products receiving FDA approval. Increased awareness and acceptance of migraine treatments among healthcare providers and patients enhance market penetration. Additionally, ongoing research and development efforts promise further innovations in this therapeutic area.

What are the weaknesses of the CGRP antagonists market in 2025?

High costs associated with CGRP antagonist therapies can limit accessibility for some patients, potentially affecting market growth. There is also a need for further long-term safety and efficacy data, which could slow adoption among conservative prescribers. Additionally, competition from other migraine treatments may pose a challenge for CGRP antagonists to capture significant market share.

What opportunities exist for the CGRP antagonists market in 2025?

Expanding indications for CGRP antagonists beyond migraines, such as cluster headaches and other pain-related conditions, could open new revenue streams. The growing global focus on personalized medicine presents opportunities for tailored therapies. Collaborations between pharmaceutical companies and healthcare systems may lead to enhanced patient access and improved treatment adherence.

What threats does the CGRP antagonists market face in 2025?

Intense competition from both established treatments and new entrants in the migraine market could pressure pricing and market share. Regulatory changes and potential policy shifts regarding drug reimbursement may also impact market dynamics. Moreover, evolving patient preferences and treatment paradigms may challenge the long-term demand for CGRP antagonists.

What are the political factors affecting the CGRP antagonists market in 2025?

Political factors such as government regulations on healthcare reimbursement policies and pricing controls for pharmaceuticals can influence the accessibility and adoption of CGRP antagonists. Additionally, healthcare policies supporting or restricting the use of newer, high-cost medications could either foster or hinder market growth, depending on the political landscape in different regions.

How do economic factors impact the CGRP antagonists market in 2025?

Economic factors, including the affordability of treatments and healthcare spending trends, play a key role in the market. The high cost of CGRP antagonists may limit adoption in low-income regions or healthcare systems with stringent budget constraints. However, in wealthier economies, increasing healthcare budgets and a focus on advanced treatments can lead to higher demand for these therapies.

What social factors influence the CGRP antagonists market in 2025?

Social factors such as increasing awareness of migraines and chronic pain conditions are driving demand for effective treatments like CGRP antagonists. Changing attitudes toward healthcare and patients’ willingness to seek out innovative therapies also play a significant role. Furthermore, social trends toward prioritizing mental and physical well-being contribute to the rising acceptance of CGRP treatments.

What technological factors affect the CGRP antagonists market in 2025?

Technological advancements in drug delivery systems, personalized medicine, and data analytics are enabling more targeted and efficient treatment options in the CGRP antagonist market. The growth of digital health technologies also enhances patient monitoring and adherence, potentially improving treatment outcomes and fostering broader use of CGRP antagonists.

What environmental factors impact the CGRP antagonists market in 2025?

Environmental factors, such as the push for sustainable manufacturing processes and eco-friendly packaging, are influencing the pharmaceutical industry. As consumers and regulators demand greener practices, CGRP antagonist producers may need to adopt more sustainable approaches, impacting production costs and brand reputation.

What legal factors affect the CGRP antagonists market in 2025?

Legal factors such as intellectual property rights, patent expirations, and regulatory approvals from agencies like the FDA influence the market. The protection of patents for CGRP antagonists ensures exclusivity and profitability for manufacturers, while generic drug approvals can increase competition, driving down prices and impacting market dynamics.

Who are the suppliers in the CGRP antagonists market in 2025?

Suppliers include pharmaceutical companies that research, develop, and manufacture CGRP antagonists, as well as raw material providers for drug formulation. Key suppliers also involve contract manufacturers, research institutions, and technology firms involved in clinical trials and the development of drug delivery systems.

What are the inputs to the CGRP antagonists market in 2025?

Inputs consist of the research and development of CGRP antagonists, clinical trial data, regulatory approvals, and raw materials required for manufacturing. Other inputs include market insights, healthcare professionals’ feedback, and the availability of treatment facilities and infrastructure to deliver these therapies.

What processes drive the CGRP antagonists market in 2025?

The processes include drug discovery and development, clinical trials, regulatory approval, manufacturing, distribution, and marketing of CGRP antagonists. After-market processes also involve patient education, prescription management, and healthcare provider engagement to improve treatment adherence.

Who are the customers of the CGRP antagonists market in 2025?

Customers include healthcare providers such as neurologists, pain management specialists, and general practitioners who prescribe CGRP antagonists for treating migraine and other pain conditions. Patients suffering from migraines and chronic pain, as well as healthcare systems and insurance companies, are also key customers.

What are the outputs of the CGRP antagonists market in 2025?

The outputs include the approved and commercially available CGRP antagonist treatments, clinical guidelines, patient outcomes, and market data reflecting the uptake and effectiveness of these therapies. Additionally, research publications and post-market surveillance data contribute to the continuous development and refinement of CGRP treatments.

What is the threat of new entrants in the CGRP antagonists market in 2025?

The threat of new entrants is moderate. While the CGRP antagonists market holds high growth potential, significant barriers to entry exist due to the high costs of research and development, regulatory approval processes, and the need for clinical validation. Established pharmaceutical companies with strong R&D capabilities dominate the market, making it challenging for new players to penetrate.

How intense is the bargaining power of suppliers in the CGRP antagonists market in 2025?

The bargaining power of suppliers is relatively low. Although raw material suppliers and contract manufacturers play an essential role in drug production, there are numerous suppliers in the market. The high level of competition among suppliers and the established partnerships between pharmaceutical companies and suppliers limit any individual supplier's power.

What is the bargaining power of buyers in the CGRP antagonists market in 2025?

The bargaining power of buyers, such as healthcare providers and patients, is moderate. While healthcare providers can influence treatment choices, patients often rely on doctor prescriptions. However, the rising cost of treatments and increasing patient demand for effective therapies give healthcare buyers some leverage, especially in competitive markets with alternative treatment options.

What is the threat of substitute products in the CGRP antagonists market in 2025?

The threat of substitutes is moderate to high. Other migraine and pain management therapies, such as triptans, anti-inflammatory drugs, and biologics, provide alternatives to CGRP antagonists. However, the unique mechanism of action and clinical effectiveness of CGRP antagonists position them as a preferred treatment option, although substitutes still pose competition.

How competitive is the CGRP antagonists market in 2025?

The market is highly competitive. Several well-established pharmaceutical companies are developing and marketing CGRP antagonists, creating intense rivalry. Additionally, the approval of generic alternatives and the emergence of new treatments add further competition, putting pressure on pricing and innovation within the market.

What are the key raw materials involved in the CGRP antagonists market in 2025?

Key raw materials include active pharmaceutical ingredients (APIs) specific to CGRP antagonists, excipients for drug formulation, and specialized compounds for biologic-based therapies. These materials are sourced from chemical suppliers, biotechnology companies, and research institutions involved in the drug development process.

What are the main factors affecting the upstream supply chain in the CGRP antagonists market in 2025?

Factors affecting the upstream supply chain include the availability of high-quality raw materials, fluctuations in production costs, and regulatory requirements related to manufacturing practices. The reliance on specialized suppliers for complex ingredients and technologies can create challenges, particularly in maintaining consistency and quality.

How do research and development activities impact the upstream dynamics of the CGRP antagonists market in 2025?

R&D activities play a crucial role in shaping the upstream dynamics, as they drive innovation in CGRP antagonist formulations and delivery methods. Investment in R&D is essential for improving efficacy, safety profiles, and addressing unmet needs in the migraine treatment landscape. The success of R&D initiatives directly influences the demand for upstream resources and the development of new therapies.

What is the role of partnerships and collaborations in the upstream segment of the CGRP antagonists market in 2025?

Partnerships and collaborations between pharmaceutical companies, biotechnology firms, and academic institutions are vital to the upstream segment. They help in pooling resources for R&D, securing supply chain stability, and accessing specialized technologies. Collaborations also facilitate the sharing of clinical data and accelerate the regulatory approval process for new treatments.

How do regulatory considerations impact the upstream activities of the CGRP antagonists market in 2025?

Regulatory considerations significantly impact upstream activities, as manufacturers must comply with stringent guidelines for drug development, production, and distribution. Adherence to FDA and EMA regulations, along with requirements for quality assurance and safety testing, can influence the pace and cost of upstream operations. Additionally, any changes in regulatory policies could affect the supply chain and manufacturing processes.

What are the key activities in the midstream segment of the CGRP antagonists market in 2025?

Key activities in the midstream segment include manufacturing, quality control, and packaging of CGRP antagonists. Additionally, this stage involves bulk distribution to wholesalers, healthcare providers, and pharmacies, as well as ensuring compliance with regulatory standards for commercialization. Logistics and inventory management also play a critical role in midstream operations.

How do distribution channels impact the midstream activities in the CGRP antagonists market in 2025?

Distribution channels significantly impact the midstream activities by determining the efficiency and reach of CGRP antagonists to various healthcare providers and pharmacies. The strength of partnerships with wholesalers, direct sales teams, and pharmacy networks influences how quickly products reach the market and patient populations. The ability to manage these channels effectively is critical to ensuring consistent supply.

What role does regulatory approval play in midstream operations for CGRP antagonists in 2025?

Regulatory approval is crucial in midstream operations, as it allows for the legal manufacturing, sale, and distribution of CGRP antagonists. The approval process impacts the timing of market entry and ensures that the products meet safety and quality standards. Delays in approval can disrupt midstream activities by postponing distribution or requiring adjustments in manufacturing practices.

What challenges exist in the midstream supply chain for CGRP antagonists in 2025?

Challenges in the midstream supply chain include ensuring sufficient production capacity, maintaining stringent quality control measures, and navigating complex distribution networks. Delays in manufacturing or distribution can affect availability and increase costs. Additionally, maintaining compliance with global regulatory standards while managing costs remains a persistent challenge in this segment.

How do partnerships between pharmaceutical companies and distributors affect the midstream dynamics of the CGRP antagonists market in 2025?

Partnerships between pharmaceutical companies and distributors are essential for the successful midstream distribution of CGRP antagonists. Strong relationships enable better forecasting, supply chain efficiency, and faster market access. These partnerships also allow for smoother coordination in managing inventory and responding to demand fluctuations, ultimately enhancing the product's availability across regions.

What are the key activities in the downstream segment of the CGRP antagonists market in 2025?

Key activities in the downstream segment include the marketing, sales, and distribution of CGRP antagonists to healthcare providers and patients. This stage also involves post-market surveillance, monitoring patient outcomes, and providing customer support. Additionally, downstream activities encompass physician education, advertising campaigns, and ensuring product availability at pharmacies.

How do healthcare providers impact the downstream dynamics in the CGRP antagonists market in 2025?

Healthcare providers, especially neurologists and pain specialists, play a critical role in the downstream segment by prescribing CGRP antagonists. Their acceptance and trust in the treatment options directly influence market demand. Educating healthcare professionals on the benefits and proper use of CGRP antagonists is key to increasing adoption rates and ensuring effective patient outcomes.

What are the challenges in patient access to CGRP antagonists in the downstream market in 2025?

Challenges in patient access include the high cost of CGRP antagonists, which can limit affordability, especially for uninsured or underinsured patients. Insurance coverage and reimbursement policies also affect access, as some payers may limit coverage for these newer therapies. Additionally, geographical disparities in healthcare infrastructure can restrict access in certain regions.

How do marketing and branding influence the downstream activities of the CGRP antagonists market in 2025?

Marketing and branding are crucial in differentiating CGRP antagonists from other treatment options and driving patient demand. Effective promotional campaigns and brand positioning help build awareness, educate patients, and foster loyalty. Physicians' perceptions, influenced by marketing, can directly impact the prescribing behavior and long-term market success.

What role do patient support programs play in the downstream segment of the CGRP antagonists market in 2025?

Patient support programs are essential in the downstream segment, as they provide financial assistance, education, and resources to help patients manage their treatment. These programs can improve adherence to prescribed therapies, provide information about CGRP antagonist usage, and reduce the burden of out-of-pocket costs, leading to better patient outcomes and higher treatment satisfaction.

Chapter 1, to describe CGRP Antagonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of CGRP Antagonists, with price, sales, revenue and global market share of CGRP Antagonists from 2018 to 2023.
Chapter 3, the CGRP Antagonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CGRP Antagonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and CGRP Antagonists market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of CGRP Antagonists.
Chapter 14 and 15, to describe CGRP Antagonists sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of CGRP Antagonists
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global CGRP Antagonists Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Monoclonal Antibodies
       1.3.3 CGRP Receptor Inhibitor
   1.4 Market Analysis by Application
       1.4.1 Overview: Global CGRP Antagonists Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Hospital
       1.4.3 Clinic
       1.4.4 Other
   1.5 Global CGRP Antagonists Market Size & Forecast
       1.5.1 Global CGRP Antagonists Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global CGRP Antagonists Sales Quantity (2018-2029)
       1.5.3 Global CGRP Antagonists Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 PFIZER INC(Biohaven)
       2.1.1 PFIZER INC(Biohaven) Details
       2.1.2 PFIZER INC(Biohaven) Major Business
       2.1.3 PFIZER INC(Biohaven) CGRP Antagonists Product and Services
       2.1.4 PFIZER INC(Biohaven) CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 PFIZER INC(Biohaven) Recent Developments/Updates
   2.2 ABBVIE INC
       2.2.1 ABBVIE INC Details
       2.2.2 ABBVIE INC Major Business
       2.2.3 ABBVIE INC CGRP Antagonists Product and Services
       2.2.4 ABBVIE INC CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 ABBVIE INC Recent Developments/Updates
   2.3 Amgen
       2.3.1 Amgen Details
       2.3.2 Amgen Major Business
       2.3.3 Amgen CGRP Antagonists Product and Services
       2.3.4 Amgen CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Amgen Recent Developments/Updates
   2.4 Teva
       2.4.1 Teva Details
       2.4.2 Teva Major Business
       2.4.3 Teva CGRP Antagonists Product and Services
       2.4.4 Teva CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Teva Recent Developments/Updates
   2.5 Eli Lilly and Company
       2.5.1 Eli Lilly and Company Details
       2.5.2 Eli Lilly and Company Major Business
       2.5.3 Eli Lilly and Company CGRP Antagonists Product and Services
       2.5.4 Eli Lilly and Company CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Eli Lilly and Company Recent Developments/Updates
   2.6 Lundbeck
       2.6.1 Lundbeck Details
       2.6.2 Lundbeck Major Business
       2.6.3 Lundbeck CGRP Antagonists Product and Services
       2.6.4 Lundbeck CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Lundbeck Recent Developments/Updates
   2.7 Novartis
       2.7.1 Novartis Details
       2.7.2 Novartis Major Business
       2.7.3 Novartis CGRP Antagonists Product and Services
       2.7.4 Novartis CGRP Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Novartis Recent Developments/Updates

3 Competitive Environment: CGRP Antagonists by Manufacturer

   3.1 Global CGRP Antagonists Sales Quantity by Manufacturer (2018-2023)
   3.2 Global CGRP Antagonists Revenue by Manufacturer (2018-2023)
   3.3 Global CGRP Antagonists Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of CGRP Antagonists by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 CGRP Antagonists Manufacturer Market Share in 2022
       3.4.2 Top 6 CGRP Antagonists Manufacturer Market Share in 2022
   3.5 CGRP Antagonists Market: Overall Company Footprint Analysis
       3.5.1 CGRP Antagonists Market: Region Footprint
       3.5.2 CGRP Antagonists Market: Company Product Type Footprint
       3.5.3 CGRP Antagonists Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global CGRP Antagonists Market Size by Region
       4.1.1 Global CGRP Antagonists Sales Quantity by Region (2018-2029)
       4.1.2 Global CGRP Antagonists Consumption Value by Region (2018-2029)
       4.1.3 Global CGRP Antagonists Average Price by Region (2018-2029)
   4.2 North America CGRP Antagonists Consumption Value (2018-2029)
   4.3 Europe CGRP Antagonists Consumption Value (2018-2029)
   4.4 Asia-Pacific CGRP Antagonists Consumption Value (2018-2029)
   4.5 South America CGRP Antagonists Consumption Value (2018-2029)
   4.6 Middle East and Africa CGRP Antagonists Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global CGRP Antagonists Sales Quantity by Type (2018-2029)
   5.2 Global CGRP Antagonists Consumption Value by Type (2018-2029)
   5.3 Global CGRP Antagonists Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global CGRP Antagonists Sales Quantity by Application (2018-2029)
   6.2 Global CGRP Antagonists Consumption Value by Application (2018-2029)
   6.3 Global CGRP Antagonists Average Price by Application (2018-2029)

7 North America

   7.1 North America CGRP Antagonists Sales Quantity by Type (2018-2029)
   7.2 North America CGRP Antagonists Sales Quantity by Application (2018-2029)
   7.3 North America CGRP Antagonists Market Size by Country
       7.3.1 North America CGRP Antagonists Sales Quantity by Country (2018-2029)
       7.3.2 North America CGRP Antagonists Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe CGRP Antagonists Sales Quantity by Type (2018-2029)
   8.2 Europe CGRP Antagonists Sales Quantity by Application (2018-2029)
   8.3 Europe CGRP Antagonists Market Size by Country
       8.3.1 Europe CGRP Antagonists Sales Quantity by Country (2018-2029)
       8.3.2 Europe CGRP Antagonists Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific CGRP Antagonists Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific CGRP Antagonists Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific CGRP Antagonists Market Size by Region
       9.3.1 Asia-Pacific CGRP Antagonists Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific CGRP Antagonists Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America CGRP Antagonists Sales Quantity by Type (2018-2029)
   10.2 South America CGRP Antagonists Sales Quantity by Application (2018-2029)
   10.3 South America CGRP Antagonists Market Size by Country
       10.3.1 South America CGRP Antagonists Sales Quantity by Country (2018-2029)
       10.3.2 South America CGRP Antagonists Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa CGRP Antagonists Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa CGRP Antagonists Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa CGRP Antagonists Market Size by Country
       11.3.1 Middle East & Africa CGRP Antagonists Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa CGRP Antagonists Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 CGRP Antagonists Market Drivers
   12.2 CGRP Antagonists Market Restraints
   12.3 CGRP Antagonists Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

   13.1 Raw Material of CGRP Antagonists and Key Manufacturers
   13.2 Manufacturing Costs Percentage of CGRP Antagonists
   13.3 CGRP Antagonists Production Process
   13.4 CGRP Antagonists Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 CGRP Antagonists Typical Distributors
   14.3 CGRP Antagonists Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global CGRP Antagonists Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global CGRP Antagonists Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. PFIZER INC(Biohaven) Basic Information, Manufacturing Base and Competitors
   Table 4. PFIZER INC(Biohaven) Major Business
   Table 5. PFIZER INC(Biohaven) CGRP Antagonists Product and Services
   Table 6. PFIZER INC(Biohaven) CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. PFIZER INC(Biohaven) Recent Developments/Updates
   Table 8. ABBVIE INC Basic Information, Manufacturing Base and Competitors
   Table 9. ABBVIE INC Major Business
   Table 10. ABBVIE INC CGRP Antagonists Product and Services
   Table 11. ABBVIE INC CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. ABBVIE INC Recent Developments/Updates
   Table 13. Amgen Basic Information, Manufacturing Base and Competitors
   Table 14. Amgen Major Business
   Table 15. Amgen CGRP Antagonists Product and Services
   Table 16. Amgen CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. Amgen Recent Developments/Updates
   Table 18. Teva Basic Information, Manufacturing Base and Competitors
   Table 19. Teva Major Business
   Table 20. Teva CGRP Antagonists Product and Services
   Table 21. Teva CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. Teva Recent Developments/Updates
   Table 23. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
   Table 24. Eli Lilly and Company Major Business
   Table 25. Eli Lilly and Company CGRP Antagonists Product and Services
   Table 26. Eli Lilly and Company CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Eli Lilly and Company Recent Developments/Updates
   Table 28. Lundbeck Basic Information, Manufacturing Base and Competitors
   Table 29. Lundbeck Major Business
   Table 30. Lundbeck CGRP Antagonists Product and Services
   Table 31. Lundbeck CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 32. Lundbeck Recent Developments/Updates
   Table 33. Novartis Basic Information, Manufacturing Base and Competitors
   Table 34. Novartis Major Business
   Table 35. Novartis CGRP Antagonists Product and Services
   Table 36. Novartis CGRP Antagonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 37. Novartis Recent Developments/Updates
   Table 38. Global CGRP Antagonists Sales Quantity by Manufacturer (2018-2023) & (K Units)
   Table 39. Global CGRP Antagonists Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 40. Global CGRP Antagonists Average Price by Manufacturer (2018-2023) & (US$/Unit)
   Table 41. Market Position of Manufacturers in CGRP Antagonists, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 42. Head Office and CGRP Antagonists Production Site of Key Manufacturer
   Table 43. CGRP Antagonists Market: Company Product Type Footprint
   Table 44. CGRP Antagonists Market: Company Product Application Footprint
   Table 45. CGRP Antagonists New Market Entrants and Barriers to Market Entry
   Table 46. CGRP Antagonists Mergers, Acquisition, Agreements, and Collaborations
   Table 47. Global CGRP Antagonists Sales Quantity by Region (2018-2023) & (K Units)
   Table 48. Global CGRP Antagonists Sales Quantity by Region (2024-2029) & (K Units)
   Table 49. Global CGRP Antagonists Consumption Value by Region (2018-2023) & (USD Million)
   Table 50. Global CGRP Antagonists Consumption Value by Region (2024-2029) & (USD Million)
   Table 51. Global CGRP Antagonists Average Price by Region (2018-2023) & (US$/Unit)
   Table 52. Global CGRP Antagonists Average Price by Region (2024-2029) & (US$/Unit)
   Table 53. Global CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 54. Global CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 55. Global CGRP Antagonists Consumption Value by Type (2018-2023) & (USD Million)
   Table 56. Global CGRP Antagonists Consumption Value by Type (2024-2029) & (USD Million)
   Table 57. Global CGRP Antagonists Average Price by Type (2018-2023) & (US$/Unit)
   Table 58. Global CGRP Antagonists Average Price by Type (2024-2029) & (US$/Unit)
   Table 59. Global CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 60. Global CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 61. Global CGRP Antagonists Consumption Value by Application (2018-2023) & (USD Million)
   Table 62. Global CGRP Antagonists Consumption Value by Application (2024-2029) & (USD Million)
   Table 63. Global CGRP Antagonists Average Price by Application (2018-2023) & (US$/Unit)
   Table 64. Global CGRP Antagonists Average Price by Application (2024-2029) & (US$/Unit)
   Table 65. North America CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 66. North America CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 67. North America CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 68. North America CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 69. North America CGRP Antagonists Sales Quantity by Country (2018-2023) & (K Units)
   Table 70. North America CGRP Antagonists Sales Quantity by Country (2024-2029) & (K Units)
   Table 71. North America CGRP Antagonists Consumption Value by Country (2018-2023) & (USD Million)
   Table 72. North America CGRP Antagonists Consumption Value by Country (2024-2029) & (USD Million)
   Table 73. Europe CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 74. Europe CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 75. Europe CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 76. Europe CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 77. Europe CGRP Antagonists Sales Quantity by Country (2018-2023) & (K Units)
   Table 78. Europe CGRP Antagonists Sales Quantity by Country (2024-2029) & (K Units)
   Table 79. Europe CGRP Antagonists Consumption Value by Country (2018-2023) & (USD Million)
   Table 80. Europe CGRP Antagonists Consumption Value by Country (2024-2029) & (USD Million)
   Table 81. Asia-Pacific CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 82. Asia-Pacific CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 83. Asia-Pacific CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 84. Asia-Pacific CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 85. Asia-Pacific CGRP Antagonists Sales Quantity by Region (2018-2023) & (K Units)
   Table 86. Asia-Pacific CGRP Antagonists Sales Quantity by Region (2024-2029) & (K Units)
   Table 87. Asia-Pacific CGRP Antagonists Consumption Value by Region (2018-2023) & (USD Million)
   Table 88. Asia-Pacific CGRP Antagonists Consumption Value by Region (2024-2029) & (USD Million)
   Table 89. South America CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 90. South America CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 91. South America CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 92. South America CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 93. South America CGRP Antagonists Sales Quantity by Country (2018-2023) & (K Units)
   Table 94. South America CGRP Antagonists Sales Quantity by Country (2024-2029) & (K Units)
   Table 95. South America CGRP Antagonists Consumption Value by Country (2018-2023) & (USD Million)
   Table 96. South America CGRP Antagonists Consumption Value by Country (2024-2029) & (USD Million)
   Table 97. Middle East & Africa CGRP Antagonists Sales Quantity by Type (2018-2023) & (K Units)
   Table 98. Middle East & Africa CGRP Antagonists Sales Quantity by Type (2024-2029) & (K Units)
   Table 99. Middle East & Africa CGRP Antagonists Sales Quantity by Application (2018-2023) & (K Units)
   Table 100. Middle East & Africa CGRP Antagonists Sales Quantity by Application (2024-2029) & (K Units)
   Table 101. Middle East & Africa CGRP Antagonists Sales Quantity by Region (2018-2023) & (K Units)
   Table 102. Middle East & Africa CGRP Antagonists Sales Quantity by Region (2024-2029) & (K Units)
   Table 103. Middle East & Africa CGRP Antagonists Consumption Value by Region (2018-2023) & (USD Million)
   Table 104. Middle East & Africa CGRP Antagonists Consumption Value by Region (2024-2029) & (USD Million)
   Table 105. CGRP Antagonists Raw Material
   Table 106. Key Manufacturers of CGRP Antagonists Raw Materials
   Table 107. CGRP Antagonists Typical Distributors
   Table 108. CGRP Antagonists Typical Customers

List of Figures

   Figure 1. CGRP Antagonists Picture
   Figure 2. Global CGRP Antagonists Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global CGRP Antagonists Consumption Value Market Share by Type in 2022
   Figure 4. Monoclonal Antibodies Examples
   Figure 5. CGRP Receptor Inhibitor Examples
   Figure 6. Global CGRP Antagonists Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 7. Global CGRP Antagonists Consumption Value Market Share by Application in 2022
   Figure 8. Hospital Examples
   Figure 9. Clinic Examples
   Figure 10. Other Examples
   Figure 11. Global CGRP Antagonists Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global CGRP Antagonists Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global CGRP Antagonists Sales Quantity (2018-2029) & (K Units)
   Figure 14. Global CGRP Antagonists Average Price (2018-2029) & (US$/Unit)
   Figure 15. Global CGRP Antagonists Sales Quantity Market Share by Manufacturer in 2022
   Figure 16. Global CGRP Antagonists Consumption Value Market Share by Manufacturer in 2022
   Figure 17. Producer Shipments of CGRP Antagonists by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 18. Top 3 CGRP Antagonists Manufacturer (Consumption Value) Market Share in 2022
   Figure 19. Top 6 CGRP Antagonists Manufacturer (Consumption Value) Market Share in 2022
   Figure 20. Global CGRP Antagonists Sales Quantity Market Share by Region (2018-2029)
   Figure 21. Global CGRP Antagonists Consumption Value Market Share by Region (2018-2029)
   Figure 22. North America CGRP Antagonists Consumption Value (2018-2029) & (USD Million)
   Figure 23. Europe CGRP Antagonists Consumption Value (2018-2029) & (USD Million)
   Figure 24. Asia-Pacific CGRP Antagonists Consumption Value (2018-2029) & (USD Million)
   Figure 25. South America CGRP Antagonists Consumption Value (2018-2029) & (USD Million)
   Figure 26. Middle East & Africa CGRP Antagonists Consumption Value (2018-2029) & (USD Million)
   Figure 27. Global CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 28. Global CGRP Antagonists Consumption Value Market Share by Type (2018-2029)
   Figure 29. Global CGRP Antagonists Average Price by Type (2018-2029) & (US$/Unit)
   Figure 30. Global CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 31. Global CGRP Antagonists Consumption Value Market Share by Application (2018-2029)
   Figure 32. Global CGRP Antagonists Average Price by Application (2018-2029) & (US$/Unit)
   Figure 33. North America CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 34. North America CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 35. North America CGRP Antagonists Sales Quantity Market Share by Country (2018-2029)
   Figure 36. North America CGRP Antagonists Consumption Value Market Share by Country (2018-2029)
   Figure 37. United States CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 38. Canada CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 39. Mexico CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Europe CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 41. Europe CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 42. Europe CGRP Antagonists Sales Quantity Market Share by Country (2018-2029)
   Figure 43. Europe CGRP Antagonists Consumption Value Market Share by Country (2018-2029)
   Figure 44. Germany CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 45. France CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 46. United Kingdom CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. Russia CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. Italy CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Asia-Pacific CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 50. Asia-Pacific CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 51. Asia-Pacific CGRP Antagonists Sales Quantity Market Share by Region (2018-2029)
   Figure 52. Asia-Pacific CGRP Antagonists Consumption Value Market Share by Region (2018-2029)
   Figure 53. China CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 54. Japan CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 55. Korea CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. India CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. Southeast Asia CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. Australia CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. South America CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 60. South America CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 61. South America CGRP Antagonists Sales Quantity Market Share by Country (2018-2029)
   Figure 62. South America CGRP Antagonists Consumption Value Market Share by Country (2018-2029)
   Figure 63. Brazil CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 64. Argentina CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 65. Middle East & Africa CGRP Antagonists Sales Quantity Market Share by Type (2018-2029)
   Figure 66. Middle East & Africa CGRP Antagonists Sales Quantity Market Share by Application (2018-2029)
   Figure 67. Middle East & Africa CGRP Antagonists Sales Quantity Market Share by Region (2018-2029)
   Figure 68. Middle East & Africa CGRP Antagonists Consumption Value Market Share by Region (2018-2029)
   Figure 69. Turkey CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 70. Egypt CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 71. Saudi Arabia CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. South Africa CGRP Antagonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. CGRP Antagonists Market Drivers
   Figure 74. CGRP Antagonists Market Restraints
   Figure 75. CGRP Antagonists Market Trends
   Figure 76. Porters Five Forces Analysis
   Figure 77. Manufacturing Cost Structure Analysis of CGRP Antagonists in 2022
   Figure 78. Manufacturing Process Analysis of CGRP Antagonists
   Figure 79. CGRP Antagonists Industrial Chain
   Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 81. Direct Channel Pros & Cons
   Figure 82. Indirect Channel Pros & Cons
   Figure 83. Methodology
   Figure 84. Research Process and Data Source